Brief buprenorphine detoxification for the treatment of prescription opioid dependence: A pilot study

Addictive Behaviors

Volumn 34, Issue 3, 2009, Pages 304-311

  Sigmon, Stacey C ^a   Dunn, Kelly E ^a   Badger, Gary J ^b   Heil, Sarah H ^a   Higgins, Stephen T ^a  

^a UNIVERSITY OF VERMONT   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Buprenorphine; Naltrexone; Opioid detoxification; Oxycodone; Prescription opioid abuse

Indexed keywords

ADULT; BEHAVIOR THERAPY; BUPRENORPHINE; EPIDEMIOLOGIC METHODS; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PRESCRIPTION DRUGS; SUBSTANCE ABUSE DETECTION; TIME FACTORS;

EID: 58149108963     PISSN: 03064603     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addbeh.2008.11.017     Document Type: Article

References (74)

1. Abbott P.J., Moore B.A., Weller S.B., and Delaney H.D. AIDS risk behavior in opioid dependent patients treated with community reinforcement approach and relationships with psychiatric disorders. Journal of Addictive Diseases 14 4 (1998) 33-48
2. Alterman A.I., Kampman K., Boardman C.R., Cacciola J.S., Rutherford M.J., McKay J.R., et al. A cocaine-positive baseline urine predicts outpatient treatment attrition and failure to attain initial abstinence. Drug and Alcohol Dependence 46 1-2 (1997) 79-85
3. Amass L., Bickel W.K., Higgins S., and Hughes J.R. A preliminary investigation of outcome following gradual or rapid buprenorphine detoxification. Journal of Addictive Diseases 13 3 (1994) 33-45
4. Armitage P. Exclusions, losses to follow-up, and withdrawals in clinical trials. In: Shapiro S.H., and Lewis T.A. (Eds). Clinical trials: Issues and approaches (1983), Marcel Dekker, Inc, New York 99-113
5. Assadi S.M., Hafezi M., Mokri A., Razzaghi E., and Pharm P.G. Opioid detoxification using high doses of buprenorphine in 24 hours: A randomized, double-blind, controlled clinical trial. Journal of Substance Abuse Treatment 27 1 (2004) 75-82
6. Azrin N.H. Improvements in the community-reinforcement approach to alcoholism. Behavior Research and Therapy 14 5 (1976) 339-348
7. Azrin N.H., Sisson R.W., Meyers R., and Godley M. Alcoholism treated by disulfiram and community reinforcement therapy. Journal of Behavior Therapy and Experimental Psychiatry 13 2 (1982) 105-121
8. Beck A.T., Epstein N., Brown G., and Steer R.A. An inventory for measuring clinical anxiety: Psychometric properties. Journal of Consulting and Clinical Psychology 56 6 (1988) 893-897
9. Beck A.T., Ward C.H., Mendelson M., Mock J., and Erbaugh J. An inventory for measuring depression. Archives of General Psychiatry 4 (1961) 561-571
10. Becker A.B., Strain E.C., Bigelow G.E., Stitzer M.L., and Johnson R.E. Gradual dose taper following chronic buprenorphine. The American Journal on Addictions 10 2 (2001) 111-121
11. Bickel W.K., Amass L., Higgins S.T., Badger G.J., and Esch R.A. Effects of adding behavioral treatment to opioid detoxification with buprenorphine. Journal of Consulting and Clinical Psychology 65 5 (1997) 803-810
12. Bickel W.K., Stitzer M.L., Bigelow G.E., Liebson I.A., Jasinski D.R., and Johnson R.E. A clinical trial of buprenorphine: Comparison with methadone in the detoxification of heroin addicts. Clinical Pharmacological Therapeutics 43 3 (1988) 72-78
13. Brands B., Blake J., Sproule B., Gourlay D., and Busto U. Prescription opioid abuse in patients presenting for methadone maintenance treatment. Drug and Alcohol Dependence 73 2 (2004) 199-207
14. Budney A.J., and Higgins S.T. A community reinforcement plus vouchers approach: Treating cocaine addiction. Rockville, MD: Department of Health and Human Services, National Institute on Drug Abuse (1998)
15. Bullingham R.E., McQuay H.J., Moore A., and Bennett M.R. Buprenorphine kinetics. Clinical Pharmacology and Therapeutics 28 5 (1980) 667-672
16. Carise D., Dugosh K.L., McLellan A.T., Camilleri A., Woody G.E., and Lynch K.G. Prescription OxyContin abuse among patients entering addiction treatment. American Journal of Psychiatry 164 11 (2007) 1750-1756
17. Carroll K.M., Sinha R., Nich C., Babuscio T., and Rounsaville B.J. Contingency management to enhance naltrexone treatment of opioid dependence: A randomized clinical trial of reinforcement magnitude. Experimental and Clinical Psychopharmacology 10 1 (2002) 54-63
18. Cicero T.J., Inciardi J.A., and Munoz A. Trends in abuse of OxyContin and other opioid analgesics in the United States: 2002-2004. The Journal of Pain 6 10 (2005) 662-672
19. Cicero T.J., Surratt H., Inciardi J.A., and Munoz A. Relationship between therapeutic use and abuse of opioid analgesics in rural, suburban, and urban locations in the United States. Phamacoepidemiology and Drug Safety 16 8 (2007) 827-840
20. Compton W.M., and Volkow N.D. Major increases in opioid analgesic abuse in the United States: Concerns and strategies. Drug and Alcohol Dependence 81 2 (2006) 103-107
21. Diamant K., Fischer G., Schneider C., Lenzinger E., Pezawas L., Schindler S., et al. Outpatient opiate detoxification treatment with buprenorphine. Preliminary Investigation. European Addiction Research 4 4 (1998) 198-202
22. Drug Abuse Warning Network (DAWN). Substance Abuse and Mental Health Services Administration, Office of Applied Studies: Trends in drug-related emergency department visits, 1994-2002 at a glance. The DAWN Report, Rockville, MD (2003)
23. Drug Abuse Warning Network (DAWN). Substance Abuse and Mental Health Services Administration, Office of Applied Studies: National Estimates of Drug-Related Emergency Department Visits, 2005. DAWN Series D-29, DHHS Publication No. (SMA) 07-4256, Rockville, MD (2007)
24. Eissenberg T., Greenwald M.K., Johnson R.E., Liebson I.A., Bigelow G.E., and Stitzer M.L. Buprenorphine's physical dependence potential: Antagonist-precipitated withdrawal in humans. Journal of Pharmacology and Experimental Therapeutics 276 2 (1996) 449-459
25. Feingold A., and Rounsaville B. Construct validity of the dependence syndrome as measured by DSM-IV for different psychoactive substances. Addiction 90 2 (1995) 1661-1669
26. Fudala P.J., Jaffe J.H., Dax E.M., and Johnson R.E. Use of buprenorphine in the treatment of opioid addiction. II. Physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal. Clinical Pharmacology and Therapeutics 47 4 (1990) 525-534
27. Gerra G., Borella F., Zaimovic A., Moi G., Bussandri M., Bubici C., et al. Buprenorphine versus methadone for opioid dependence: Predictor variables for treatment outcome. Drug and Alcohol Dependence 75 1 (2004) 37-45
28. Gonzalez J.P., and Brogden R.N. Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs 35 3 (1988) 192-213
29. Hambrook, J.M., & Rance, M.J., (1976). The interaction of buprenorphine with the opiate receptor: Lipophilicity as a determining factor in drug-receptor kinetics. In: Kosterlitz, H.W. (Ed). Opiates and Endogenous Opioid Peptides, Amsterdam: Elsevier/North Holland, Biomedical Press, pp 295-301.
30. Higgins S.T., Sigmon S.C., Wong C.J., Heil S.H., Badger G.J., Donham R., et al. Community-reinforcement therapy for cocaine-dependent outpatients. Archives of General Psychiatry 60 10 (2003) 1043-1052
31. Himmelsbach C.K. The morphine abstinence syndrome, its nature and treatment. Annals of Internal Medicine 15 (1941) 829-839
32. Hunt G.M., and Azrin N.H. A community-reinforcement approach to alcoholism. Behaviour Research and Therapy 11 1 (1973) 91-104
33. Iguchi M.Y., and Stitzer M.L. Predictors of opiate drug abuse during a 90-day methadone detoxification. American Journal of Drug and Alcohol Abuse 17 (1991) 279-294
34. Jasinski D.R., Pevnick J.S., and Griffith J.D. Human pharmacology and abuse potential of the analgesic buprenorphine: A potential agent for treating narcotic addiction. Archives of General Psychiatry 35 4 (1978) 501-516
35. Johnson R.E., Jaffe J.H., and Fudala P.J. A controlled trial of buprenorphine treatment for opioid dependence. Journal of the American Medical Association 267 10 (1992) 2750-2755
36. Johnston L.D., O'Malley P.M., and Bachman J.G. Monitoring the future national results on adolescent drug use: Overview of key findings, 2001. NIH Publication No. 02-5105 (2002), National Institute on Drug Abuse, Bethesda, MD
37. Johnson R.E., Strain E.C., and Amass L. Buprenorphine: How to use it right. Drug and Alcohol Dependence 70 Suppl. 2 (2003) S59-S77
38. Kampman K.M., Pettinati H.M., Volpicelli J.R., Oslin D.M., Lipkin C., Sparkman T., et al. Cocaine dependence severity predicts outcome in outpatient detoxification from cocaine and alcohol. American Journal of Addiction 13 1 (2004) 74-82
39. Knudsen H.K., Ducharme L.J., and Roman P.M. Controlled-release oxycodone admissions in public and private substance abuse treatment: Associations with organizational characteristics. Journal of Addictive Diseases 26 1 (2007) 41-50
40. Kosten T.R., and Kleber H.D. Buprenorphine detoxification from opioid dependence: A pilot study. Life Sciences 42 2 (1989) 635-641
41. Kosten T.R., Morgan C., and Kleber H.D. Treatment of heroin addicts using buprenorphine. American Journal on Drug and Alcohol Abuse 17 2 (1991) 119-128
42. Ling W., Amass L., Shoptaw S., Annon J.J., Hillhoise M., Babcock D., et al., Buprenorphine Study Protocol Group. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: Findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction 100 8 (2005) 1090-1100
43. Lintzeris N. Buprenorphine dosing regime in the management of out-patient heroin withdrawal. Drug and Alcohol Review 21 1 (2002) 39-45
44. Lintzeris N., Bell J., Bammer G., Jolley D.J., and Rushworth L. A randomized controlled trial of buprenorphine in the management of short-term ambulatory heroin withdrawal. Addiction 97 11 (2002) 1395-1404
45. Marsch L., Bickel W.K., Badger G.J., Stothart M.E., Quesnel K.J., Stanger C., et al. Comparison of pharmacological treatments for opioid-dependent adolescents. Archives of General Psychiatry 62 10 (2005) 1157-1164
46. Martin W.R., Jasinski D.R., and Mansky P.A. Naltrexone, an antagonist for the treatment of heroin dependence. Effects in man. Archives in General Psychiatry 28 6 (1973) 784-791
47. McCabe S.E., Boyd C.J., and Teter C.J. Illicit use of opioid analgesics by high school seniors. Journal of Substance Abuse Treatment 28 3 (2005) 225-230
48. McCabe S.E., Boyd C.J., and Young A. Medical and nonmedical use of prescription drugs among secondary school students. Journal of Adolescent Health 40 1 (2007) 76-83
49. McCabe S.E., Teter C.J., Boyd C.J., Knight J.R., and Wechsler H. Nonmedical use of prescription opioids among U.S. college students: Prevalence and correlates from a national study. Addictive Behaviors 30 4 (2005) 798-805
50. McLellan A.T., Luborsky L., and Cacciola J. New data from the addiction severity index: Reliability and validity in three centers. Journal of Nervous and Mental Disease 173 7 (1985) 412-423
51. Mello N.K., Mendelson J.H., Kuehnle J.C., and Sellers M.S. Operant analysis of human heroin self-administration and the effects of naltrexone. Journal of Pharmacology and Experimental Therapeutics 216 1 (1981) 45-54
52. Moore B., Fiellin D.A., Barry D.T., Sullivan L.E., Chawarski M.C., O'Connor P.G., et al. Primary care office-based buprenorphine treatment: Comparison of heroin and prescription opioid dependent patients. Journal of General Internal Medicine 22 4 (2007) 527-530
53. National Survey on Drug Use and Health (NSDUH) report. Nonmedical oxycodone users: A comparison with heroin users (2005). http://www.oas.samhsa.gov Office of Applied Studies publication, available online at http://www.oas.samhsa.gov
54. O'Connor P.G., Carroll K.M., Shi J.M., Schottenfeld R.S., Kosten T.R., and Rounsaville B.J. Three methods of opioid detoxification in a primary care setting. Annals of Internal Medicine 127 7 (1997) 526-530
55. Office of National Drug Control Policy (ONDCP). State of Vermont: Profile of drug indicators (2008), Drug Policy Information Clearinghouse, Rockville, MD
56. Peachey J.E., and Lei H. Assessment of opioid dependence with naloxone. British Journal of Addiction 83 2 (1988) 193-201
57. Preston K.L., Bigelow G.E., and Liebson I.A. Buprenorphine and naloxone alone and in combination in opioid-dependent humans. Psychopharmacology 94 (1988) 484-490
58. Preston K.L., Silverman K., Higgins S.T., Brooner R.K., Montoya I., Schuster C.R., et al. Cocaine use early in treatment predicts outcome in a behavioral treatment program. Journal of Consulting and Clinical Psychology 66 4 (1998) 691-696
59. Preston K.L., Silverman K., Umbricht A., DeJesus A., Montoya I.D., and Schuster C.R. Improvement in naltrexone treatment compliance with contingency management. Drug and Alcohol Dependence 54 2 (1999) 127-135
60. Resnick R. Methadone detoxification from illicit opiates and methadone maintenance. In: Cooper J.R., Altman F., Brown B.S., and Czechowicz D. (Eds). Research on the Treatment of Narcotic Addiction: State of the Art. NIDA Treatment Research Monograph Series no. 83-1281 (1983), US Government Printing Office, Washington, DC 160-167
61. Rosenblum A., Parrino M., Schnoll S.H., Fong C., Maxwell C., Cleland C.M., et al. Prescription opioid abuse among enrollees into methadone maintenance treatment. Drug and Alcohol Dependence 90 1 (2007) 64-71
62. Selzer M.L. The Michigan Alcoholism Screening Test: The quest for a new diagnostic instrument. American Journal of Psychiatry 127 12 (1971) 1653-1658
63. Sigmon S.C. Characterizing the emerging population of prescription opioid abusers. The American Journal on Addictions 15 3 (2006) 208-212
64. Silverman K., Chutuape M.A., Bigelow G.E., and Stitzer M.L. Voucher-based reinforcement of cocaine abstinence in treatment-resistant methadone patients: Effects of reinforcement magnitude. Psychopharmacology 146 2 (1999) 128-138
65. Soyka M., Zingg C., Koller G., and Kuefner H. Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: Results from a randomized study. International Journal of Neuropsychopharmacology 11 (2008) 641-653
66. Substance Abuse and Mental Health Services Administration (SAMHSA). Federal Register: Opioid drugs in maintenance and detoxification treatment of opiate addiction, final rule. 21 CFR Part 29, 142 CFR Part 8. Department of Health and Human Services, Rockville, MD (2001)
67. Substance Abuse and Mental Health Services Administration (SAMHSA). Office of Applied Studies, Results from the 2002 National Survey on Drug Use and Health: National Findings. NHSDA Series H-22, DHHS Publication No. (SMA) 03-3836), Rockville, MD (2003)
68. Substance Abuse and Mental Health Services Administration (SAMHSA). Results from the 2006 National Survey on Drug Use and Health. National Findings (Office of Applied Studies, NSDUH Series H-32, DHHS Publication No. SMA 07-4293). Rockville, MD (2007)
69. Substance Abuse and Mental Health Services Administration (SAMHSA). Treatment Episode Data Set (TEDS) Highlights - 2006 National Admissions to Substance Abuse Treatment Services. (Office of Applied Studies Series #S-40, DHHS Publication No. (SMA) 08-4313), Rockville, MD (2007)
70. Sung H.-E., Richter L., Vaughan R., Johnson P., and Thom B. Nonmedical use of prescription opioids among teenagers in the United States: Trends and correlates. Journal of Adolescent Health 37 1 (2005) 44-51
71. Treatment Episode Data Set (TEDS). National Admissions to Substance Abuse Treatment Services: 1992-2002. (DASIS Series: S-23, DHHS Publication No. (SMA) 04-3965), Rockville, MD (2004)
72. Umbricht A., Montoya I.D., Hoover D.R., Demuth K.L., Chiang C.T., and Preston K.L. Naltrexone shortened opioid detoxification with buprenorphine. Drug and Alcohol Dependence 56 3 (1999) 181-190
73. Verebey K., Volavka J., Mule S.J., and Resnick R.B. Naltrexone: Disposition, metabolism, and effects after acute and chronic dosing. Clinical Pharmacology and Therapeutics 20 3 (1976) 315-328
74. Zacny J., Bigelow G., Compton P., Foley K., Iguchi M., and Sannerud C. College on Problems of Drug Dependence taskforce on prescription opioid non-medical use and abuse: Position statement. Drug and Alcohol Dependence 69 3 (2003) 215-232